Table 1. Results Biomechanical Testing.
| N | unfractured femur | fracture | ratio | p-value* | ||
|---|---|---|---|---|---|---|
| V-max | 15 | Enoxaparin | 140.1 ± 17.1 | 22.9 ± 08.1 | 0.16 ± 0.05 | <0.001 |
| (N) | Control | 142.1 ± 20.8 | 24.7 ± 11.9 | 0.18 ± 0.11 | <0.001 | |
| Rivaroxaban | 136.0 ± 20.5 | 25.3 ± 11.3 | 0.19 ± 0.09 | <0.001 | ||
| Stiffness | 14 | Enoxaparin | 227.1 ± 29.5 | 18.4 ± 07.2 | 0.08 ± 0.03 | <0.001 |
| Control | 231.0 ± 50.5 | 27.8 ± 22.4 | 0.12 ± 0.10 | <0.001 | ||
| Rivaroxaban | 214.1 ± 48.1 | 23.1 ± 14.4 | 0.12 ± 0.08 | <0.001 | ||
| Work to failure | 15 | Enoxaparin | 13.8 ± 4.9 | |||
| (Nmm) | Control | 15.5 ± 8.3 | ||||
| Rivaroxaban | 15.4 ± 6.5 |
Results of biomechanical testing (Mean ± SD, *one sample / paired samples t-test). N = 15 (except for assessments involving stiffness in the Enoxaparin and Rivaroxaban groups, here n = 14). p-value displays difference between experimental and control sides.